NASDAQ$QURE
uniQure NV · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
uniQure announced its Q3 2023 financial results, highlighting FDA clearance of IND application for AMT-260, progress in clinical trials for AMT-130, and a strategic reorganization for cost savings.
uniQure reported Q3 2023 revenues of $1.4 million, consistent with the previous year. The company experienced a net loss of $89.6 million, compared to a $47.9 million loss in the same period of 2022. They announced FDA clearance for AMT-260 and are on track to provide a clinical update on AMT-130. A strategic reorganization is expected to save $180 million over three years, with a strong cash position of approximately $660 million.
- Received FDA clearance for Investigational New Drug application for AMT-260 in refractory mesial temporal lobe epilepsy.
- On track to provide a clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease later in the fourth quarter of 2023.
- uniQure and CSL won the 2023 Prix Galien USA award for HEMGENIX®.
- Announced a strategic reorganization expected to deliver $180 million of cost savings over the next three years.
Headline financials
Revenue & EPS history
uniQure · Revenue · Quarterly
$1.41M
Forward guidance
uniQure expects continued progress on HEMGENIX® commercialization, plans to announce follow-up data from AMT-130 trials, aims to submit an IND for AMT-191, and anticipates initiating patient screening for AMT-162 and AMT-260.
Tailwinds
- Continued progress on the commercialization of HEMGENIX®
- Plans to announce follow up data from the U.S. and European Phase I/II clinical study of AMT-130 in 2023
- Expectation to submit an investigational new drug application for AMT-191 in Fabry disease in 2023 and begin patient dosing in 2024
- Expectation to initiate patient screening in AMT-162 and AMT-260 in the fourth quarter of 2023
- Begin patient dosing in each in the first quarter of 2024
Headwinds
- Risks associated with the regulatory approval and commercial launch of HEMGENIX®
- Material changes to our interim or preliminary data
- Impact of financial and geopolitical events on our Company and the wider economy and health care system
- Company’s ability to raise additional capital to support late stage development of the Company’s clinical program(s) if supported by future data
- Risks, uncertainties and other factors described under the heading "Risk Factors" in the Company’s periodic securities filings
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.6%
Avg return
30 days after
59%
27 / 46 earnings
Positive
+47.1%
Q2 2015
Best reaction
-32.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +34.0% | +35.5% | |
| Q4 2025 | -32.7% | -8.7% | +8.1% | |
| Q3 2025 | -6.0% | +7.5% | -27.5% | |
| Q1 2025 | +3.3% | +17.0% | +15.8% | |
| Q4 2024 | +3.4% | -2.9% | +6.9% | |
| Q3 2024 | +28.8% | +40.1% | +18.5% | |
| Q2 2024 | -4.6% | -1.3% | -23.6% | |
| Q1 2024 | +3.6% | +4.2% | +12.5% | |
| Q4 2023 | -14.8% | -23.6% | -23.0% | |
| Q3 2023 | +6.5% | -0.8% | +19.5% | |
| Q2 2023 | -3.0% | -9.2% | -16.0% | |
| Q1 2023 | +2.7% | +1.2% | -3.8% | |
| Q4 2022 | +5.0% | +6.2% | +1.3% | |
| Q3 2022 | +4.4% | +0.1% | +38.2% | |
| Q2 2022 | -25.5% | -20.2% | -18.4% | |
| Q1 2022 | +6.6% | -2.0% | -5.2% | |
| Q4 2021 | +5.9% | +13.0% | +4.5% | |
| Q3 2021 | -0.3% | +7.1% | +2.2% | |
| Q2 2021 | +8.5% | +11.5% | +10.7% | |
| Q1 2021 | +0.7% | -0.3% | +12.3% | |
| Q4 2020 | -2.0% | -11.5% | -8.2% | |
| Q3 2020 | -10.6% | -7.0% | +7.0% | |
| Q2 2020 | +10.7% | +12.0% | +3.7% | |
| Q1 2020 | +1.0% | -3.2% | +6.6% | |
| Q4 2019 | +1.5% | +1.4% | -11.3% | |
| Q3 2019 | -0.8% | +3.9% | +13.4% | |
| Q2 2019 | -8.5% | -9.1% | -17.1% | |
| Q1 2019 | -2.0% | +2.4% | +5.4% | |
| Q4 2018 | +7.7% | +11.8% | +12.1% | |
| Q3 2018 | +9.0% | +0.5% | +20.1% | |
| Q2 2018 | +6.6% | +9.3% | +21.9% | |
| Q1 2018 | -0.3% | -3.2% | +15.7% | |
| Q4 2017 | -13.5% | -17.2% | +16.9% | |
| Q3 2017 | -2.6% | +4.4% | +4.4% | |
| Q2 2017 | +7.2% | +5.1% | +4.8% | |
| Q1 2017 | +2.3% | +3.3% | +6.6% | |
| Q4 2016 | +1.0% | -3.1% | -10.5% | |
| Q3 2016 | -6.2% | -3.9% | -20.6% | |
| Q1 2016 | +11.8% | +16.8% | -38.5% | |
| Q3 2015 | -12.0% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q2 2015 | +47.1% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro